HOW WE DID IT
MoFo represented iota Biosciences’ (“iota”) from its inception in 2017 and through its acquisition by Astellas Pharma Inc. (“Astellas”) in 2020. Our Life Sciences + Healthcare industry team continues to represent iota post-acquisition, focusing on iota’s overall IP strategy and protecting its pioneering technology.
iota was founded to build upon the award-winning ultrasound technology invented at the University of California, Berkeley. The company’s proprietary bioelectronics technology enables power transfer and wireless communication with implantable medical devices. iota continues to explore the application of its technologies to help transform the way doctors manage and treat numerous diseases, including bladder and neural disorders.
In 2020, our team counseled iota as it navigated its acquisition by Astellas for a total deal value of over $400 million. Following the acquisition, we have continued to represent iota on IP diligence as well as advising on the company’s developing IP.
Background
While leveraging our team’s deep roots in science and technology, we have served as a strategic partner to iota in crafting legal strategies that protect iota’s IP strategy, all in support of establishing a high-value portfolio that has driven the company from start-up to acquisition, and as a result, given meaningful stake to the company. We continue to protect iota’s technology as the company develops several innovative, life-changing products.
The Result
MoFo Team
Jonathan Bockman
Partner, Washington, D.C.
Of Counsel, Palo Alto
Ethan M. Weiner
View Jonathan's
Bio
View Ethan's
Bio
MoFo Team
Result
Background
Protecting Pioneering Technology
Iota Biosciences
CASE STUDY
Michel Maharbiz
CEO, iota Biosciences, Inc.
MoFo's knowledge of the science and the team's ability to strategically navigate niche medical technologies naturally made them the right legal partner for us.
“
”
Background
The Result
“
”
MoFo Team